Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), “natural immune function” (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentrations (ID 3089) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
Meta data
Keywords
Bifidobacterium animalis ssp. lactis Bb-12, pathogens, microorganisms, LDL-cholesterol, immune, inflammation, health claims
On request from
European Commission
Question Number
EFSA-Q-2008-1711
EFSA-Q-2008-2206
EFSA-Q-2008-3821
EFSA-Q-2008-1650
EFSA-Q-2008-1653
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Contact
Competing interests: One member of the Panel did not participate in the discussion on the subject referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of interests.
Abstract
No abstract available
© European Food Safety Authority, 2011